166 related articles for article (PubMed ID: 16095008)
1. A longitudinal study of calprotectin in patients with polymyalgia rheumatica or temporal arteritis: relation to disease activity.
Brun JG; Madland TM; Gran JT; Myklebust G
Scand J Rheumatol; 2005; 34(2):125-8. PubMed ID: 16095008
[TBL] [Abstract][Full Text] [Related]
2. Plasma adrenomedullin levels in patients with polymyalgia rheumatica and giant cell arteritis.
Garcia-Unzueta MT; Martínez-Taboada VM; Amado-Señarís JA; Rodríguez-Valverde V
Clin Exp Rheumatol; 2006; 24(2 Suppl 41):S6-9. PubMed ID: 16859588
[TBL] [Abstract][Full Text] [Related]
3. Alpha 1-antichymotrypsin, C-reactive protein and erythrocyte sedimentation rate in polymyalgia rheumatica and giant cell arteritis.
Pountain GD; Calvin J; Hazleman BL
Br J Rheumatol; 1994 Jun; 33(6):550-4. PubMed ID: 8205403
[TBL] [Abstract][Full Text] [Related]
4. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.
Kyle V; Hazleman BL
Ann Rheum Dis; 1989 Aug; 48(8):658-61. PubMed ID: 2782975
[TBL] [Abstract][Full Text] [Related]
5. [Polymyalgia rheumatica].
Nishikai M
Nihon Rinsho; 1999 Feb; 57(2):370-3. PubMed ID: 10078007
[TBL] [Abstract][Full Text] [Related]
6. Fibrin(ogen)olysis in polymyalgia rheumatica and temporal arteritis: preliminary findings on association with disease activity.
Grau RG; Kassan SS; Franks JJ; Kaplan H; Walker SH; Tan EM
Ann Rheum Dis; 1984 Oct; 43(5):721-4. PubMed ID: 6497463
[TBL] [Abstract][Full Text] [Related]
7. [Rheumatic polymyalgia and temporal arteritis. Case contribution and bibliographic review].
Manganelli P; Mercadanti M; Nervetti A; Ambanelli U
Minerva Med; 1987 Mar; 78(5):287-96. PubMed ID: 3822219
[TBL] [Abstract][Full Text] [Related]
8. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients.
Myklebust G; Gran JT
Scand J Rheumatol; 2001; 30(5):260-7. PubMed ID: 11727839
[TBL] [Abstract][Full Text] [Related]
9. Monocyte chemoattractant protein 1 (MCP-1) in temporal arteritis and polymyalgia rheumatica.
Ellingsen T; Elling P; Olson A; Elling H; Baandrup U; Matsushima K; Deleuran B; Stengaard-Pedersen K
Ann Rheum Dis; 2000 Oct; 59(10):775-80. PubMed ID: 11005777
[TBL] [Abstract][Full Text] [Related]
10. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up.
Kyle V; Cawston TE; Hazleman BL
Ann Rheum Dis; 1989 Aug; 48(8):667-71. PubMed ID: 2782977
[TBL] [Abstract][Full Text] [Related]
11. High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica.
van Sleen Y; Boots AMH; Abdulahad WH; Bijzet J; Sandovici M; van der Geest KSM; Brouwer E
Rheumatology (Oxford); 2020 Jan; 59(1):176-184. PubMed ID: 31292652
[TBL] [Abstract][Full Text] [Related]
12. Polymyalgia rheumatica and giant cell arteritis--An ophthalmic emergency.
Durkin SR; Athanasiov PA; Crompton JL
Aust Fam Physician; 2006 Nov; 35(11):889-91. PubMed ID: 17099810
[TBL] [Abstract][Full Text] [Related]
13. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica.
van der Geest KS; Abdulahad WH; Rutgers A; Horst G; Bijzet J; Arends S; Roffel MP; Boots AM; Brouwer E
Rheumatology (Oxford); 2015 Aug; 54(8):1397-402. PubMed ID: 25724206
[TBL] [Abstract][Full Text] [Related]
14. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis.
Myklebust G; Gran JT
Br J Rheumatol; 1996 Nov; 35(11):1161-8. PubMed ID: 8948307
[TBL] [Abstract][Full Text] [Related]
15. Relationship of the erythrocyte sedimentation rate to acute phase proteins in polymyalgia rheumatica and giant cell arteritis.
Park JR; Jones JG; Hazleman BL
Ann Rheum Dis; 1981 Oct; 40(5):493-5. PubMed ID: 6171213
[TBL] [Abstract][Full Text] [Related]
16. Serum amyloid A concentrations in giant-cell arteritis and polymyalgia rheumatica: a useful test in the management of the disease.
Hachulla E; Saile R; Parra HJ; Hatron PY; Gosset D; Fruchart JC; Devulder B
Clin Exp Rheumatol; 1991; 9(2):157-63. PubMed ID: 1711943
[TBL] [Abstract][Full Text] [Related]
17. Soluble interleukin 2 receptors in polymyalgia rheumatica/giant cell arteritis. Clinical and laboratory correlations.
Salvarani C; Macchioni P; Boiardi L; Rossi F; Casadei Maldini M; Mancini R; Beltrandi E; Spacca C; Lodi L; Portioli I
J Rheumatol; 1992 Jul; 19(7):1100-6. PubMed ID: 1512765
[TBL] [Abstract][Full Text] [Related]
18. The ESR in the diagnosis and management of the polymyalgia rheumatica/giant cell arteritis syndrome.
Ellis ME; Ralston S
Ann Rheum Dis; 1983 Apr; 42(2):168-70. PubMed ID: 6847261
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of fibronectin in polymyalgia rheumatica giant cell arteritis.
Puccetti L; Marotta G; Remorini E; Lucchetti A; Zuccotti M; Petrini G; Baicchi U; Ciompi ML
Rheumatol Int; 1987; 7(6):249-54. PubMed ID: 3125593
[TBL] [Abstract][Full Text] [Related]
20. [Follow-up studies in polymyalgia rheumatica and temporal arteritis].
Li J; Tang FL; Wang XD; Yu JH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Dec; 24(6):643-5. PubMed ID: 12905697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
